Press & news

FluoGuide develops surgical solutions that are expected to reduce suffering for the patient and increase the likelihood of cure as well as reducing costs for the health care system.

New exchange: Nasdaq First North

FluoGuide is moving from Spotlight to Nasdaq First North. Shareholders are strongly encouraged to make sure they will be able to freely trade their shares in the future.

New exchange: Nasdaq First North

2023

25 January, 2023 CFO acquired shares in FluoGuide News Corporate Information Other Corporate Information English IR
FluoGuide A/S (“FluoGuide” or the “Company”) announce that the CFO of FluoGuide, Henrik Hang, has acquired...
9 January, 2023 FluoGuide releases positive interim result of FG001 in head and neck cancer News Corporate Information Other Corporate Information English Regulatory MAR IR
Copenhagen, Denmark, 9 January 2023 - FluoGuide A/S ("FluoGuide" or the "Company") is pleased to announce the positive...

2022

24 November, 2022 FluoGuide A/S publishes interim report for the period January – September 2022 News English Regulatory Listing Regulation Report Interim Q3 IR
In Q3 2022, FluoGuide made important progress and received approvals from Danish authorities to initiate the clinical phase IIb trial...
21 November, 2022 FluoGuide has enrolled the first patient in the phase IIa trial in head and neck cancer News Corporate Information Other Corporate Information English IR
The phase IIa trial is designed to obtain proof-of-concept in head and neck cancer for our uPAR platform technology used to guide surgical...
8 November, 2022 FluoGuide reaches milestone with FG001 for phase III clinical supply News Corporate Information Other Corporate Information English IR
FluoGuide has successfully collaborated with its supplier PolyPeptide since the very first synthesis of the FG001 API (Active Pharmaceutical...
FluoGuide has evaluated data from 8 patients in the exploratory phase IIa trial in patients with non-small cell lung cancer (NSCLC)...
20 October, 2022 FluoGuide has enrolled the first patient in the phase IIb trial in aggressive brain cancer News Corporate Information Other Corporate Information English IR
In the phase IIb trial, FG001 is being tested as a standalone treatment compared to Gliolan (5-ALA), which is the only approved product...
6 October, 2022 Presentation of phase l/lla clinical data of FG001 in aggressive brain cancer at the European Congress of Neurosurgery 2022 News Corporate Information Other Corporate Information English IR
The excellent phase l/lla clinical data of FG001 in aggressive brain cancer will be presented by Principal Investigator and Chief Surgeon...
Andreas Kjaer, Professor and CSO at FluoGuide presented the excellent phase I/IIa clinical data of FG001 in aggressive brain cancer...